Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, Yamada A, Fujita T; Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators. Ando K, et al. Hypertens Res. 2010 Jun;33(6):616-21. doi: 10.1038/hr.2010.46. Epub 2010 Apr 9. Hypertens Res. 2010. PMID: 20379190 Clinical Trial.
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR).
Yokoyama H, Sugiyama H, Sato H, Taguchi T, Nagata M, Matsuo S, Makino H, Watanabe T, Saito T, Kiyohara Y, Nishi S, Iida H, Morozumi K, Fukatsu A, Sasaki T, Tsuruya K, Kohda Y, Higuchi M, Kiyomoto H, Goto S, Hattori M, Hataya H, Kagami S, Yoshikawa N, Fukasawa Y, Ueda Y, Kitamura H, Shimizu A, Oka K, Nakagawa N, Ito T, Uchida S, Furuichi K, Nakaya I, Umemura S, Hiromura K, Yoshimura M, Hirawa N, Shigematsu T, Fukagawa M, Hiramatsu M, Terada Y, Uemura O, Kawata T, Matsunaga A, Kuroki A, Mori Y, Mitsuiki K, Yoshida H; Committee for the Standardization of Renal Pathological Diagnosis and for Renal Biopsy and Disease Registry of the Japanese Society of Nephrology, and the Progressive Renal Disease Research of the Ministry of Health, Labour and Welfare of Japan. Yokoyama H, et al. Clin Exp Nephrol. 2012 Dec;16(6):903-20. doi: 10.1007/s10157-012-0673-8. Epub 2012 Oct 11. Clin Exp Nephrol. 2012. PMID: 23053590
Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials.
Higashijima Y, Tanaka T, Nangaku M. Higashijima Y, et al. Among authors: nangaku m. Expert Opin Drug Discov. 2013 Aug;8(8):965-76. doi: 10.1517/17460441.2013.796358. Epub 2013 May 4. Expert Opin Drug Discov. 2013. PMID: 23642028 Review.
Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I, Kono H, Nakatani E, Morita S, Tsubakihara Y, Akizawa T. Imai E, et al. Among authors: nangaku m. Clin Exp Nephrol. 2016 Feb;20(1):71-6. doi: 10.1007/s10157-015-1133-z. Epub 2015 Jun 17. Clin Exp Nephrol. 2016. PMID: 26081567 Clinical Trial.
How the Target Hemoglobin of Renal Anemia Should Be.
Mimura I, Tanaka T, Nangaku M. Mimura I, et al. Among authors: nangaku m. Nephron. 2015;131(3):202-9. doi: 10.1159/000440849. Epub 2015 Sep 19. Nephron. 2015. PMID: 26381503 Free article. Review.
763 results